Plain-English translation of NCT06136949 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Researchers are studying a protein called STARD3 that appears to play a role in colorectal cancer. This observational study will examine tissue and blood samples from colorectal cancer patients to understand whether this protein could help doctors diagnose cancer better and predict which treatments will work best for each patient.
Colorectal cancer is a common and serious disease, and doctors need better ways to identify which patients will respond to specific treatments. This study aims to determine if STARD3 could serve as a marker to guide treatment decisions and help predict how patients will respond to therapy.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning you will not receive any medication or treatment as part of the trial. Researchers will use tissue and blood samples you've already provided to the study center's biobank, along with your medical information, to study the STARD3 protein and how it relates to cancer progression and treatment response. The study is designed to track outcomes over time as you receive your regular cancer care.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Italy
Enrollment target
~150 participants
Started
May 2023
Primary completion
December 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vincenzo Canzonieri, MD, PhD
Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.